Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection

Chattopadhyay, Anasuya; Park, Steven; Delmas, Guillaume; Suresh, Rema; Senina, Svetlana; Perlin, David S.; Rose, John K.

doi:10.1016/j.vaccine.2008.09.031

Cited by 30 publications

(23 citation statements)

References 65 publications

(88 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It encodes five structural proteins: nucleocapsid (N), phosphoprotein (P), matrix (M), glycoprotein (G), and RNAdependent RNA polymerase (L). VSV-based vectors expressing appropriate foreign antigens have been shown to be highly effective vaccines against numerous viral and bacterial pathogens (2,10,15,16,18,(27)(28)(29)32). We constructed live attenuated or single-cycle recombinant VSVs (lacking VSV G) expressing either NiV G or F. All vectors induced neutralizing antibodies to NiV pseudotypes.…”

mentioning

confidence: 99%

Complementing Defective Viruses That Express Separate Paramyxovirus Glycoproteins Provide a New Vaccine Vector Approach

Chattopadhyay

Rose

2011

J Virol

Self Cite

View full text Add to dashboard Cite

Replication-defective vaccine vectors based on vesicular stomatitis virus (VSV) lacking its envelope glycoprotein gene (G) are highly effective in animal models. However, such ⌬G vectors are difficult to grow because they require complementation with the VSV G protein. In addition, the complementing G protein induces neutralizing antibodies in animals and thus limits multiple vector applications. In the process of generating an experimental Nipah virus (a paramyxovirus) vaccine, we generated two defective VSV⌬G vectors, each expressing one of the two Nipah virus (NiV) glycoproteins (G and F) that are both required for virus entry to host cells. These replication-defective VSV vectors were effective at generating NiV neutralizing antibody in mice. Most interestingly, we found that these two defective viruses could be grown together and passaged in tissue culture cells in the absence of VSV G complementation. This mixture of complementing defective viruses was also highly effective at generating NiV neutralizing antibody in animals. This novel approach to growing and producing a vaccine from two defective viruses could be generally applicable to vaccine production for other paramyxoviruses or for other viruses where the expression of at least two different proteins is required for viral entry. Such an approach minimizes biosafety concerns that could apply to single, replicationcompetent VSV recombinants expressing all proteins required for infection.

show abstract

mentioning

confidence: 99%

Complementing Defective Viruses That Express Separate Paramyxovirus Glycoproteins Provide a New Vaccine Vector Approach

Chattopadhyay

Rose

2011

J Virol

Self Cite

View full text Add to dashboard Cite

show abstract

“…STAT4-deficient mice lack the capacity to mount robust type 1 immune responses, and our recent studies indicate that the protection mediated by F1-and LcrV-specific antibody benefits from gamma interferon (IFN-␥) and tumor necrosis factor alpha (TNF-␣), cytokine products of type 1 immunity (21). Chattopadhyay et al recently demonstrated that protection conferred by immunizing mice with an LcrVexpressing viral vector benefits from the presence of CD4 T cells at the time of challenge (6). Together, these observations raise the possibility that high-titer antibody may not suffice to protect humans from pneumonic plague and suggest that vaccines harnessing both humoral and cellular defense mechanisms should provide superior defense (38,39).…”

mentioning

confidence: 99%

D27-pLpxL, an Avirulent Strain of Yersinia pestis , Primes T Cells That Protect against Pneumonic Plague

et al. 2009

View full text Add to dashboard Cite

“…Thus, T cells appear to enhance the protective impact of prophylactic CpG ODN treatment. Prior studies have shown that T cells can contribute to protection against Y. pestis infection (9,38,(54)(55)(56)(57)(58).…”

Section: Discussionmentioning

confidence: 99%

Intranasal Prophylaxis with CpG Oligodeoxynucleotide Can Protect against Yersinia pestis Infection

et al. 2013

View full text Add to dashboard Cite

Immunomodulatory agents potentially represent a new class of broad-spectrum antimicrobials. Here, we demonstrate that prophylaxis with immunomodulatory cytosine-phosphate-guanidine (CpG) oligodeoxynucleotide (ODN), a toll-like receptor 9 (TLR9) agonist, confers protection against Yersinia pestis, the etiologic agent of plague. The data establish that intranasal administration of CpG ODN 1 day prior to lethal pulmonary exposure to Y. pestis strain KIM D27 significantly improves survival of C57BL/6 mice and reduces bacterial growth in hepatic tissue, despite paradoxically increasing bacterial growth in the lung. All of these CpG ODN-mediated impacts, including the increased pulmonary burden, are TLR9 dependent, as they are not observed in TLR9-deficient mice. The capacity of prophylactic intranasal CpG ODN to enhance survival does not require adaptive immunity, as it is evident in mice lacking B and/or T cells; however, the presence of T cells improves long-term survival. The prophylactic regimen also improves survival and reduces hepatic bacterial burden in mice challenged intraperitoneally with KIM D27, indicating that intranasal delivery of CpG ODN has systemic impacts. Indeed, intranasal prophylaxis with CpG ODN provides significant protection against subcutaneous challenge with Y. pestis strain CO92 even though it fails to protect mice from intranasal challenge with that fully virulent strain.

show abstract

Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection

Cited by 30 publications

References 65 publications

Complementing Defective Viruses That Express Separate Paramyxovirus Glycoproteins Provide a New Vaccine Vector Approach

Complementing Defective Viruses That Express Separate Paramyxovirus Glycoproteins Provide a New Vaccine Vector Approach

D27-pLpxL, an Avirulent Strain of Yersinia pestis , Primes T Cells That Protect against Pneumonic Plague

Intranasal Prophylaxis with CpG Oligodeoxynucleotide Can Protect against Yersinia pestis Infection

Contact Info

Product

Resources

About